Quantum BioPharma Ltd. (NASDAQ: QNTM) announced its inclusion in a BioMedWire editorial that examines the potential of its lead drug candidate, Lucid-MS, to overcome the limitations of current multiple sclerosis (MS) treatments. The editorial highlights the U.S. Food and Drug Administration's (FDA) clearance for Quantum to launch a Phase 2 clinical trial of Lucid-MS, a patented, first-in-class therapy designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system.
According to the BioMedWire editorial, the trial would mark the first time a drug based on this mechanism is tested in people living with MS. This represents a significant departure from existing MS therapies, which primarily focus on modulating or suppressing the immune system to reduce relapses but do not directly address myelin damage, the underlying cause of disability progression in MS.
Lucid-MS is a patented new chemical entity that has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. By targeting myelin repair, Lucid-MS could potentially slow or even reverse disease progression, offering new hope for patients who do not respond adequately to current treatments. The Phase 2 trial will be the first human study of this approach, and its outcomes could shape the future of MS therapy.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of Lucid-MS.
In addition to its MS program, Quantum invented UNBUZZD(TM), an over-the-counter product spun out to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
This news is important because it signals a potential paradigm shift in MS treatment. If Lucid-MS proves successful in clinical trials, it could become the first therapy to directly repair myelin damage, addressing a critical unmet need for millions of MS patients worldwide. The global MS market is projected to reach billions of dollars, and a disease-modifying therapy with a novel mechanism could capture significant share. For investors, Quantum BioPharma's progress with Lucid-MS and its additional royalty stream from Unbuzzd may represent a compelling opportunity. The Phase 2 trial's initiation will be a key milestone to watch, as positive results could lead to accelerated development and partnering discussions.
For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
